Oral mosapride can provide additional anti-emetic efficacy following total joint arthroplasty under general anesthesia: a randomized, double-blinded clinical trial

Table 6 Other clinical outcomes

	Control (n = 80)	Dexa (n = 82)	Mosa+Dexa (n = 78)	p*	p1^†	p2^†	p3^†
Time to first defecation (h)	60.7 ± 24.6	54.7 ± 15.8	36.4 ± 18.3	< 0.001	0.136	< 0.001	< 0.001
Appetite on POD 0	2.26 ± 0.67	2.34 ± 0.65	2.55 ± 0.68	0.020	0.731	0.019	0.117
Appetite on POD 1	2.38 ± 0.62	2.41 ± 0.63	2.76 ± 0.51	< 0.001	0.905	< 0.001	0.001
Appetite on POD 2	2.63 ± 0.49	2.73 ± 0.45	2.82 ± 0.45	0.030	0.306	0.022	0.443
Time to first ambulation (h)	23.4 ± 5.8	23.3 ± 4.6	20.6 ± 5.9	0.002	0.976	0.005	0.008
Satisfaction	7.7 ± 1.1	8.7 ± 1.1	9.2 ± 0.9	< 0.001	< 0.001	< 0.001	0.008
Length of hospitalization (d)	5.6 ± 1.5	5.1 ± 1.5	4.9 ± 1.4	0.013	0.095	0.012	0.683

Data presented as mean ± standard deviation. Dexa, dexamethasone; Mosa, mosapride; POD, postoperative day
p1, Control vs Dexa; p2, Control vs. Mosa+Dexa; p3, Dexa vs. Mosa-Dexa. *p values with one-way ANOVA or Wilcoxon signed-rank test and ^†p values with Tukey post hoc test

ISSN: 1471-2253